† People involved in the organization of the challenge. ‡ People contributing data from their institutions.§ Equal senior authors.

Background The 3D breast magnetic resonance fingerprinting (MRF) technique enables T1 and T2 mapping in breast tissues. Combined repeatability and reproducibility studies on breast T1 and T2 relaxometry are lacking. Purpose To assess test–retest and two‐visit repeatability and interscanner reproducibility of the 3D breast MRF technique in a single‐institution setting. Study Type Prospective. Subjects Eighteen women (median age 29 years, range, 22–33 years) underwent Visit 1 scans on scanner 1. Ten of these women underwent test–retest scan repositioning after a 10‐minute interval. Thirteen women had Visit 2 scans within 7–15 days in same menstrual cycle. The remaining five women had Visit 2 scans in the same menstrual phase in next menstrual cycle. Five women were also scanned on scanner 2 at both visits for interscanner reproducibility. Field Strength/Sequence Two 3T MR scanners with the 3D breast MRF technique. Assessment T1 and T2 MRF maps of both breasts. Statistical Tests Mean T1 and T2 values for normal fibroglandular tissues were quantified at all scans. For variability, between and within‐subjects coefficients of variation (bCV and wCV, respectively) were assessed. Repeatability was assessed with Bland–Altman analysis and coefficient of repeatability (CR). Reproducibility was assessed with interscanner coefficient of variation (CoV) and Wilcoxon signed‐rank test. Results The bCV at test–retest scans was 9–12% for T1, 7–17% for T2, wCV was <4% for T1, and <7% for T2. For two visits in same menstrual cycle, bCV was 10–15% for T1, 13–17% for T2, wCV was <7% for T1 and <5% for T2. For two visits in the same menstrual phase, bCV was 6–14% for T1, 15–18% for T2, wCV was <7% for T1, and <9% for T2. For test–retest scans, CR for T1 and T2 were 130 msec and 11 msec. For two visit scans, CR was <290 msec for T1 and 10–14 msec for T2. Interscanner CoV was 3.3–3.6% for T1 and 5.1–6.6% for T2, with no differences between interscanner measurements (P = 1.00 for T1, P = 0.344 for T2). Data Conclusion 3D breast MRF measurements are repeatable across scan timings and scanners and may be useful in clinical applications in breast imaging. Level of Evidence: 2 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;50:1133–1143.

Although machine learning (ML) has shown promise across disciplines, out-of-sample generalizability is concerning. This is currently addressed by sharing multi-site data, but such centralization is challenging/infeasible to scale due to various limitations. Federated ML (FL) provides an alternative paradigm for accurate and generalizable ML, by only sharing numerical model updates. Here we present the largest FL study to-date, involving data from 71 sites across 6 continents, to generate an automatic tumor boundary detector for the rare disease of glioblastoma, reporting the largest such dataset in the literature (n = 6, 314). We demonstrate a 33% delineation improvement for the surgically targetable tumor, and 23% for the complete tumor extent, over a publicly trained model. We anticipate our study to: 1) enable more healthcare studies informed by large diverse data, ensuring meaningful results for rare diseases and underrepresented populations, 2) facilitate further analyses for glioblastoma by releasing our consensus model, and 3) demonstrate the FL effectiveness at such scale and task-complexity as a paradigm shift for multi-site collaborations, alleviating the need for data-sharing.

Accurate differentiation between tumor progression (TP) and pseudoprogression remains a critical unmet need in neurooncology. 18 Ffluciclovine is a widely available synthetic amino acid PET radiotracer. In this study, we aimed to assess the value of 18 F-fluciclovine PET for differentiating pseudoprogression from TP in a prospective cohort of patients with suspected radiographic recurrence of glioblastoma. Methods: We enrolled 30 glioblastoma patients with radiographic progression after first-line chemoradiotherapy for whom surgical resection was planned. The patients underwent preoperative 18 Ffluciclovine PET and MRI. The relative percentages of viable tumor and therapy-related changes observed in histopathology were quantified and categorized as TP ($50% viable tumor), mixed TP (,50% and .10% viable tumor), or pseudoprogression (#10% viable tumor). Results: Eighteen patients had TP, 4 had mixed TP, and 8 had pseudoprogression. Patients with TP/mixed TP had a significantly higher 40-to 50-min SUV max (6.64 1 1.88 vs. 4.11 6 1.52, P 5 0.009) than patients with pseudoprogression. A 40-to 50-min SUV max cutoff of 4.66 provided 90% sensitivity and 83% specificity for differentiation of TP/mixed TP from pseudoprogression (area under the curve [AUC], 0.86). A maximum relative cerebral blood volume cutoff of 3.672 provided 90% sensitivity and 71% specificity for differentiation of TP/mixed TP from pseudoprogression (AUC, 0.779). Combining a 40to 50-min SUV max cutoff of 4.66 and a maximum relative cerebral blood volume of 3.67 on MRI provided 100% sensitivity and 80% specificity for differentiating TP/mixed TP from pseudoprogression (AUC, 0.95). Conclusion: 18 F-fluciclovine PET uptake can accurately differentiate pseudoprogression from TP in glioblastoma, with even greater accuracy when combined with multiparametric MRI. Given the wide availability of 18 F-fluciclovine, larger, multicenter studies are warranted to determine whether amino acid PET with 18 F-fluciclovine should be used in the routine posttreatment assessment of glioblastoma.

The purpose of this study is to test the feasibility of applying a dual-input two-compartment liver perfusion model to patients with different pathologies. A total of 7 healthy subjects and 11 patients with focal liver lesions, including 6 patients with metastatic adenocarcinoma and 5 with hepatocellular carcinoma (HCC), were examined. Liver perfusion values were measured from both focal liver lesions and cirrhotic tissues (from the 5 HCC patients). Compared to results from volunteer livers, significantly higher arterial fraction, fractional volume of the interstitial space, and lower permeability-surface area product were observed for metastatic lesions, and significantly higher arterial fraction and lower vascular transit time were observed for HCCs (P < 0.05). Significantly lower arterial fraction and higher vascular transit time, fractional volume of the vascular space, and fractional volume of the interstitial space were observed for metastases in comparison to HCCs (P < 0.05). For cirrhotic livers, a significantly lower total perfusion, lower fractional volume of the vascular space, higher fractional volume of the interstitial space, and lower permeability-surface area product were noted in comparison to volunteer livers (P < 0.05). Our findings support the possibility of using this model with 3D free-breathing acquisitions for lesion and diffuse liver disease characterization.